Form 4: TransMedics Group Executive Tamer Khayal Reports Stock Transactions

Tamer Khayal, Chief Commercial Officer of TransMedics Group, reports the exercise of stock options and subsequent sale of shares to cover tax obligations.

Summary

• On March 8, 2024, Tamer Khayal, the Chief Commercial Officer of TransMedics Group, exercised stock options to acquire 100 shares of common stock at a price of $16.14.
• Simultaneously, Khayal sold 100 shares at $90.04 and 1,317 shares at $87.63 to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Khayal directly owns 25,185 shares of TransMedics Group common stock.
• Khayal also indirectly owns 14,776 shares through the Khayal Family 2021 Irrevocable Trust and 11,051 shares through the Tamer Ibrahim Ahmed Khayal Trust.
• The initial transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are typical for executives who receive stock options and restricted stock units as part of their compensation packages.
• The use of a Rule 10b5-1 trading plan is a common strategy to avoid accusations of insider trading.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of a pre-arranged trading plan and involve a relatively small number of shares.

Key Dates